The annual incidence rate of pancreatic cancer in China is 5.1/100,000, and the number of new cases is about 50,000-60,000 every year, which is significantly higher than 20 years ago, and there is a trend of year-on-year increase and increasing youthfulness. It is a malignant tumor of the gastrointestinal tract with insidious clinical manifestations, rapid development and very poor prognosis, currently, 80% of the patients are already in advanced stage when they are diagnosed and have lost the chance of surgery, only about 20% of the patients can be treated surgically and the 5-year survival rate after surgery is less than 5%. Therefore, the early diagnosis and treatment of pancreatic cancer in the middle and late stages is a real problem that pancreatic surgeons must face in their clinical work. The surgical resection rate of early stage pancreatic cancer is 90%~100%, and the 5-year survival rate is up to 70%~100%, compared with the progressive stage pancreatic cancer, there is a great contrast in its treatment outcome. Then how can we improve the early diagnosis rate of pancreatic cancer? After widely learning from domestic and international experiences, we propose to perform a series of reasonable, effective and fast examinations from general clinical tests to tumor genetic tests and from general imaging to PET-CT for patients who are at high risk of pancreatic cancer and suspected of pancreatic cancer, which greatly improve the early diagnosis rate of pancreatic cancer and win valuable treatment time for pancreatic cancer patients. High-risk groups of pancreatic cancer: Currently recognized high-risk groups of pancreatic cancer include: (1) those who are older than 40 years old and have non-specific discomfort in the upper abdomen; (2) those who have a family history of pancreatic cancer; (3) those who have sudden onset of diabetes, especially atypical diabetes, are older than 60 years old, lack a family history, are not obese, and soon develop insulin resistance; 40% of pancreatic cancer patients have diabetes at the time of diagnosis. (4) Chronic pancreatitis is an important precancerous lesion in a small number of patients, especially chronic familial pancreatitis and chronic calcific pancreatitis; (5) Intraductal papillary mucinous neoplasm is also a precancerous lesion; (6) Those with familial adenomatous polyposis; (7) Those with benign lesions undergoing major distal gastric resection, especially those who are more than 20 years postoperative; (8) Smoking, heavy alcohol consumption, and long-term exposure to (8) Smoking, heavy alcohol consumption, and long-term exposure to harmful chemicals, etc. Diagnosis of pancreatic cancer: For patients with high risk of pancreatic cancer and clinical suspicion of pancreatic cancer, non-invasive tests are preferred for screening, such as ultrasound, CT, MRI, MRCP and serological tumor markers. Combined detection of tumor markers with imaging findings can improve the positive rate and help in early diagnosis of pancreatic cancer. The collection of pure pancreatic fluid using ERCP examination and brushing of exfoliated cells for cytological examination, oncogene mutation and tumor marker detection is an important advancement in the early diagnosis of pancreatic cancer in recent years. The detection of K-ras gene mutation in peripheral plasma has the advantages of being less invasive, rapid and accurate, and reproducible, and is mainly used for the screening of high-risk groups of pancreatic cancer, which may open up new prospects for early diagnosis of pancreatic cancer. In addition, many new imaging methods have gradually started to be applied in the early diagnosis of pancreatic cancer, such as pancreatic ductoscopy, intrapancreatic ductal ultrasound, dynamic spiral CT with 3D reconstruction, PET, etc., which can enable the detection of more and more small pancreatic cancers. Especially, the status of PET in the early diagnosis of pancreatic cancer has been recognized, and related studies have shown that pancreatic cancer.